Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,000 Shares of Company Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the sale, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This trade represents a 18.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86.
• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $111.84, for a total value of $782,880.00.

Oruka Therapeutics Stock Down 3.7%

Shares of Oruka Therapeutics stock traded down $2.81 during trading on Thursday, reaching $73.87. The company’s stock had a trading volume of 1,222,106 shares, compared to its average volume of 1,090,003. The firm’s 50-day moving average is $93.48 and its two-hundred day moving average is $79.88. Oruka Therapeutics, Inc. has a 52-week low of $25.11 and a 52-week high of $115.51. The company has a market cap of $4.89 billion, a price-to-earnings ratio of -36.39 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. GAMMA Investing LLC raised its position in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $67,000. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at approximately $91,000. Finally, Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after purchasing an additional 2,033 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ORKA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. UBS Group boosted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Wedbush set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 24th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $128.91.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.